Back to search

Ireland· IE-PA-PA1347/058/002

Septanazal 1 mg/ 50 mg in 1 ml nasal spray solution

A xylometazoline product containing xylometazoline hydrochloride + dexpanthenol, registered in Ireland by KRKA, d.d., Novo mesto. The same ATC class is registered in 10 of our 19 countries.

ATC R01AB06

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedSeptanazal 1 mg/ 50 mg in 1 ml nasal …ATCR01AB06REGISTER NO.IE-PA-PA1347/058/002PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Xylometazoline is registered in 10 of 19 countries.

Countries holding a registration under ATC R01AB06 (xylometazoline), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 7 of them publish a price we can compare per daily dose

Xylometazoline · ATC R01AB06

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Xylometazoline hydrochloride + Dexpanthenol
Manufacturer
KRKA, d.d., Novo mesto
Country
Ireland (IE)
ATC code
R01AB06
ATC class
Xylometazoline
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA1347/058/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

63 interactions on record for xylometazoline.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Xylometazoline · interactions on record

63 records

  • 6 severe
  • 54 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • MethysergideN02CA04severe

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Xylometazoline in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All xylometazoline products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Nasic, Nasic Pur
  • Bulgaria · Nasic назик, Ксилазол
  • Cyprus · Hexarhinal Plus, Hexarhinal Plus Kids
  • Czechia · Nasic, Olynth Plus
  • Germany · Nasenduo Kinder, Nasic
  • Denmark · Zymelin Care
  • Estonia · Otrinazil, Septanazal
  • Spain · Septanasal
  • Finland · Septanazal
  • United Kingdom (Northern Ireland) · Sudafed Plus Blocked Nose
  • Greece · Hexarhinal Plus, Hexarhinal Plus Kids
  • Croatia · Ksilometazolin/Dekspantenol Pliva, Nasic
  • Hungary · Actifed, Actifed Kid
  • Lithuania · Galathenal, Olydex
  • Luxembourg · Nasenduo Nasenspray Kinder, Xyloduo Nasenspray
  • Latvia · Galathenal, Olydex
  • Malta · Septanazal
  • Norway · Xylodex
  • Poland · Nasic, Otrivin Regeneracja
  • Portugal · Nasex Duo, Septanazal Para Adultos
  • Romania · Bixtonim Xylo Duo, Nasic
  • Slovenia · Nasic, Olynth Combo
  • Slovakia · Nasal Duo Active, Nasic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ae816a58-47d9-4b37-a7ed-b6010806736f
GET /v1/drugs/ae816a58-47d9-4b37-a7ed-b6010806736f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Nasal spray, solution",
  "routes": [
    "Nasal use"
  ],
  "source": "hpra",
  "atc_all": [
    "R01AB",
    "R01AB06"
  ],
  "strength": null,
  "pa_number": "PA1347/058/002",
  "substances": [
    "Xylometazoline hydrochloride",
    "Dexpanthenol"
  ],
  "legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
  "market_info": "Not marketed",
  "authorised_at": "02/12/2016",
  "dispensing_status": "Product not subject to medical prescription",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about xylometazoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.